Currentblue cross blue shield - tennesseePolicy N/A

Human Immunodeficiency Virus (HIV) — HIV screening, viral load, and resistance testing coverage criteria

Defines coverage criteria for HIV screening, viral load quantification, and HIV genotypic/phenotypic resistance testing for members of the payer; describes indications, limitations, and tests covered.

Policy Summary

Payerblue cross blue shield - tennessee

PolicyHIV screening, viral load, and resistance testing coverage criteria

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionOrder genotypic resistance testing for patients at entry into care, with virologic failure, during pregnancy when indicated, or prior to initiating doravirine; document HIV RNA and clinical rationale.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

ages 11-65recommended initial and repeat screening population

>=90 daysminimum interval for repeat HIV screening

20-40 c/mLassay sensitivity (RT-PCR)

200 c/mLassay agreement threshold

>200 c/mLresistance testing virologic threshold

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for HIV Testing and Resistance Assays

Covered indications

Covered when ALL of the following are met according to indication group

Initial and repeat screening: For individuals 11 to 65 years of age: initial screening MEETS COVERAGE CRITERIA; repeat screening (no less than 90 days after initial) MEETS COVERAGE CRITERIA.age 11-65; >=90 days

Genotyping/Phenotyping indications: Genotyping or phenotyping MEETS COVERAGE CRITERIA for any of: prior to initiating doravirine (required), failed antiviral therapy, suboptimal viral load reduction, noncompliance with therapy, to guide treatment in acute/recent infection (within 6 months), antiretroviral-naïve entering treatment, and for all HIV-infected pregnant individuals in specified situations.acute/recent within 6 months

Baseline HIV quantification: Plasma quantification of HIV-1 or HIV-2 RNA MEETS COVERAGE CRITERIA before initiation of antiretroviral therapy; for those with detectable HIV RNA; and in at-risk individuals with persistent borderline/equivocal serologic reactivity or signs/symptoms of acute retroviral syndrome.

Medically Necessary Indications for Resistance Testing

Covered when ALL of the following are met

Initial treatment/genotypic testing: Genotypic drug-resistance testing is recommended at entry into care to guide selection of initial ART (AII); do not delay ART for results. If therapy is deferred, repeat testing may be considered at ART initiation (CIII). Genotypic testing is preferred over phenotypic testing for ART‑naive patients.HIV RNA >500 to 1,000 copies/mL (see guidance)

Virologic failure: Resistance testing is recommended for persons with virologic failure to assist selection of active drugs; recommended for HIV-RNA >1,000 copies/mL (AI), for 501–1,000 copies/mL (AIII), and for confirmed 201–500 copies/mL (CIII). Perform testing while on ART or within 4 weeks of stopping non-long-acting agents.see text

Testing may be unsuccessful at low viral loads but should be considered.

Pregnancy-related testing: Genotypic testing should be performed before initiating ART in pregnant people and for those entering pregnancy with detectable HIV-RNA while on therapy; do not delay ART initiation while awaiting results; modify regimen as needed once results available.

Virologic failure / resistance testing

Covered when criteria below are met as per guideline recommendations

Resistance testing for virologic failure: Perform drug-resistance testing in patients on combination ART with HIV-RNA >200 copies/mL; strongly recommended for >1,000 copies/mL (AI) and recommended for 501–1,000 copies/mL (AIII). Testing should be done while the patient is taking ART or within 4 weeks after discontinuing non-long-acting agents; for long-acting CAB/rilpivirine regimens or CAB-LA exposure, test regardless of time since discontinuation.>200 copies/mL (preferably >1,000 copies/mL)

Testing while on failing regimen preferred; >4 weeks off non-long-acting drugs may miss mutations

Baseline and pregnancy testing

Baseline and special-population testing

Baseline testing for ART-naive and pregnancy: Genotypic resistance testing is recommended at entry into HIV care for ART-naive patients to guide initial ART; recommended for all pregnant people before initiation of ART and for those entering pregnancy with detectable HIV-RNA while on therapy. Treatment should not be delayed awaiting results; if INSTI use is planned or transmitted INSTI resistance is a concern, supplement with INSTI-specific genotypic assay.NA

Proviral DNA genotyping

Testing when changing/switching regimens

Proviral DNA/genotype when suppressed or low-level viremia: Proviral DNA resistance assays may be useful in patients with HIV RNA below detection or low-level viremia, or with unavailable resistance history when considering switches; routine proviral DNA genotyping is not recommended and results should be interpreted cautiously because proviral assays may miss prior mutations and may detect clinically irrelevant variants.NA

HIV-2 monitoring and resistance

HIV-2 specific recommendations

HIV-2 monitoring and resistance: Measure HIV-2 viral load at 1, 3 and 6 months after starting or changing ART if pre-treatment viral load was detectable, then every 3–6 months; if pre-treatment viral load was undetectable, measure at 1 month then every 6 months. Perform resistance testing at diagnosis, prior to treatment initiation, and at virological failure if HIV-2 viral load ≥500 copies/mL.≥500 copies/mL for resistance testing

Repeat viral load if maximally suppressed then becomes detectable.

Routine and risk-based HIV screening

Covered when following screening recommendations are met

Routine screening: Screen adolescents and adults per USPSTF recommendations: routinely screen adolescents and adults aged 15 to 65, and screen younger/older persons at increased risk; screen adolescents under 15 who are at increased risk.age and risk-based per USPSTF

AAP pediatric guidance: Perform STI/HIV screening annually starting at 11 years and ensure at least one HIV screening between 15 and 18; rescreen youth at increased risk at least annually and up to every 3–6 months if high risk.age and risk criteria per AAP/Bright Futures

Pregnancy screening: Screen all pregnant women for HIV, including those in labor who are untested and whose HIV status is unknown.pregnancy and unknown/untested status

Not covered

Not covered: Routine combined genotyping and phenotyping DOES NOT MEET COVERAGE CRITERIA. Drug susceptibility phenotype prediction using genotypic comparison to known genotypic/phenotypic databases DOES NOT MEET COVERAGE CRITERIA.

Routine combined use of genotypic and phenotypic resistance assays is explicitly listed as not meeting coverage criteria in this policy because available published literature does not demonstrate that combined routine testing is required or provides additional benefit for patient diagnosis or management. The policy therefore states that routine combined genotyping and phenotyping DOES NOT MEET COVERAGE CRITERIA and that requests for routine combined testing may be denied.

Historic guidance cited a <3,000 copies/mL threshold for caution when interpreting low-positive HIV RNA results because older assays produced false positives at that level. The policy notes that modern plasma viral load assays have improved performance, and that any positive quantitative HIV RNA in the setting of a negative or indeterminate antibody test is now highly consistent with acute infection; low-positive results at or below 3,000 copies/mL should be repeated on a new specimen for confirmation rather than assumed to be false positive.

The policy indicates that proviral DNA genotyping may have utility in select situations (for example, persons with multiple virologic failures, absent prior resistance history, or low-level viremia at the time of a switch). However, because proviral DNA assays can fail to detect prior resistance and may identify clinically irrelevant mutations, the document states that routine proviral DNA genotyping is currently not recommended for virologically suppressed persons switching therapy.

Laboratory-developed tests (LDTs) are performed and validated within individual laboratories and are regulated under CLIA as high-complexity tests. The policy notes that LDTs are not FDA-cleared or FDA-approved and that, while FDA clearance is not required for clinical use, payers may request laboratory validation documentation before covering LDTs.

Within the reference section cited, there are no additional explicit coverage exclusions beyond those stated elsewhere in the policy; the policy summary notes that no explicit coverage exclusions are stated in this reference section.

The policy reiterates that routine combined genotyping and phenotyping and drug-susceptibility phenotype prediction derived solely from genotypic database comparisons do not meet coverage criteria due to insufficient published evidence supporting routine use.

The policy acknowledges limitations of resistance testing at low viral loads. Studies of next-generation sequencing and proviral DNA indicate variable detection at low-level viremia, and DHHS guidance notes that testing performed at low HIV RNA levels (for example, levels below commonly used resistance-testing thresholds) may be unsuccessful. Therefore, resistance testing performed at very low viral loads (for example, below ~500 copies/mL) may fail to yield reliable results and should be interpreted with caution.

While proviral DNA genotyping can be useful in specific clinical scenarios (multiple prior failures, unavailable resistance history, or low-level viremia when considering a regimen switch), the policy emphasizes that routine proviral DNA genotyping prior to switching to 2-drug therapy or for all virologically suppressed patients is not recommended.

In this portion of the reference material, the policy does not include additional explicit statements labeling services as not medically necessary beyond those already specified elsewhere; the document notes that no explicit not-medically-necessary statements are present in this segment.

Procedure Codes, Assay Ranges, and Testing Thresholds

Antibody and antigen assaysCPTCovered

86689	Antibody; HTLV or HIV antibody, confirmatory test (eg, Western Blot)
86701	Antibody; HIV-1
86702	Antibody; HIV-2
86703	Antibody; HIV-1 and HIV-2, single result
87389	Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies, single result

Antigen/NAAT assaysCPTCovered

87390	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; HIV-1
87391	Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; HIV-2
87534	Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, direct probe technique
87535	Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, amplified probe technique, includes reverse transcription when performed
87536	Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, quantification, includes reverse transcription when performed
87537	Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, direct probe technique
87538	Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, amplified probe technique, includes reverse transcription when performed
87539	Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, quantification, includes reverse transcription when performed
87806	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies

Genotype/phenotype and screening HCPCS/CPT codesmixedCovered

87900	Infectious agent drug susceptibility phenotype prediction using regularly updated genotypic bioinformatics
87901	Infectious agent genotype analysis by nucleic acid (DNA or RNA); HIV-1
87903	Infectious agent phenotype analysis by nucleic acid (DNA or RNA) with drug resistance tissue culture analysis, HIV 1; first through 10 drugs tested
87904	Infectious agent phenotype analysis by nucleic acid (DNA or RNA) with drug resistance tissue culture analysis, HIV 1; each additional drug tested
87906	Infectious agent genotype analysis by nucleic acid (DNA or RNA); HIV-1, other region (eg, integrase, fusion)
0219U	Infectious agent (human immunodeficiency virus), targeted viral next-generation sequence analysis (ie, protease [PR], reverse transcriptase [RT], integrase [INT]), algorithm reported as prediction of antiviral drug susceptibility
G0432	Infectious agent antibody detection by enzyme immunoassay (EIA) technique, HIV-1 and/or HIV-2, screening
G0433	Infectious agent antibody detection by enzyme-linked immunosorbent assay (ELISA) technique, HIV-1 and/or HIV-2, screening
G0435	Infectious agent antibody detection by rapid antibody test, HIV-1 and/or HIV-2, screening
G0475	HIV antigen/antibody, combination assay, screening

1–10 of 11

1/2

Applicable CPT/HCPCS procedure codesmixed

No codes listed

Covered/Relevant Codesmixed

affected codes

Placeholder - document part provided does not list specific CPT/HCPCS/ICD codes.

Assay sensitivity and meaningful change (detection limits, agreement threshold, meaningful change)

Analytical sensitivity of common RT-PCR assaysPrimary commercial RT-PCR tests detect approximately 20–40 copies/mL of HIV-1 RNA

Assay agreement thresholdUsing a 200 copies/mL threshold improves agreement between assays

Meaningful virologic changeChanges in HIV-1 RNA must exceed ≥0.5 log10 (≈threefold) to be considered biologically relevant

Resistance testing viral load threshold (>500 to 1,000 copies/mL)

Typical resistance-testing viral load threshold>500 to 1,000 copies/mL for performing genotypic/phenotypic resistance testing

Provider Requirements, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization and Coverage

Prior authorization may be required for certain HIV resistance and quantitative tests. Providers should submit clinical rationale and supporting documentation per payer requirements; check member benefit and applicable state/federal rules.

Prior authorization: confirm with member benefits and applicable government rules (LCD/NCD/Medicaid).
If requested, include required clinical documentation (see documentation callout).

Denial Risk

Routine Combined Genotype + Phenotype Not Covered

Routine combined genotype plus phenotype testing and genotype-based phenotype prediction do not meet coverage criteria and requests may be denied unless specific clinical circumstances justify both tests.

Routine combined genotype + phenotype: not covered.

Background, Definitions, and Technical Notes

BACKGROUND: Human immunodeficiency virus (HIV) is an RNA retrovirus that infects CD4 cells and, if untreated, can progress to AIDS. The policy focuses on management tools used in care: plasma HIV-1 and HIV-2 RNA quantification for monitoring and genotype and phenotype assays to detect and characterize antiretroviral resistance. Genotypic testing is generally preferred for initial and virologic-failure evaluations; phenotypic testing may be used for suspected multidrug or complex resistance. These testing strategies inform selection and modification of antiretroviral therapy in clinical scenarios such as entry into care, virologic failure, pregnancy, and when baseline quantification is indicated.

Definition: HIV

Definition of HIVHuman immunodeficiency virus (HIV) is an RNA retrovirus that infects CD4 cells and can lead to progressive immune deterioration and AIDS

Major subtypesHIV-1 is the predominant global subtype; HIV-2 is less common and regionally concentrated

Clinical consequenceUntreated infection can progress to AIDS with susceptibility to opportunistic infections and HIV-related cancers

Policy Summary

Payerblue cross blue shield - tennessee

PolicyHIV screening, viral load, and resistance testing coverage criteria

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

SourceLink

On This Page

HIV RNA >500 to 1,000 copies/mL (guideline thresholds)

Phenotypic testing indicated for treatment-experienced persons thought to have multidrug resistance.

Integrase testing: If transmitted INSTI resistance is suspected or there is prior use of long-acting cabotegravir (CAB-LA) as PrEP, genotypic testing should include the integrase gene (may require separate order).clinical suspicion or CAB-LA exposure

Recommended (AIII).

Use in pregnant peopleResistance testing recommended to guide regimen selection when HIV RNA >500 to 1,000 copies/mL; do not delay ART initiation

Action when VL 501–1,000 copies/mLTesting may be unsuccessful but should still be considered (BII/AIII guidance)

Viral load monitoring interval for stable patients

Usual monitoring interval for stable patientsMeasure HIV viral load every 3 to 4 months in routine follow-up

Extended interval after sustained suppressionMay extend monitoring to every 6 months for patients suppressed >1 year and clinically stable

Early monitoring after ART changesMeasure at 4–8 weeks after ART initiation or modification to assess initial response (DHHS)

Resistance testing viral load thresholds (HIV-1 and HIV-2)

General HIV-1 resistance testing thresholdResistance testing is recommended for persons with HIV-RNA >200 copies/mL (preferred thresholds higher for stronger recommendation)

DHHS graded thresholds>1,000 copies/mL (AI); 501–1,000 copies/mL (AIII); confirmed 201–500 copies/mL (CIII)

HIV-2 specific thresholdFor HIV-2, perform resistance testing at diagnosis, prior to treatment initiation, and at virologic failure if VL ≥500 copies/mL

Aptima HIV-1 Quant assay quantitation range

Aptima HIV-1 Quant assay quantitation range30 to 10,000,000 copies/mL (FDA-approved range)

Regulatory statusFDA-approved for quantitation and diagnostic use (approval updated 2020)

PlatformRuns on Hologic Panther automated system

Abbott RealTime HIV-1 quantitation range

Abbott RealTime HIV-1 quantitation range40 to 10,000,000 copies/mL (per FDA approval)

Assay typeIn vitro reverse transcription–PCR (RT‑PCR) assay for HIV‑1 RNA quantitation on the m2000 System

Regulatory statusFDA-approved (May 2007) for clinical quantitation

Genotype-based phenotype prediction using databases: not covered.

Note

Thresholds for Resistance Testing

Resistance testing is generally recommended when viral load exceeds standard thresholds; commonly used operational thresholds are >500 to 1,000 copies/mL, with some guidance supporting testing at >200 copies/mL in specific clinical scenarios. Consider that testing may be unsuccessful at lower RNA levels but still can be considered.

Common operational threshold: >500 to 1,000 copies/mL for resistance testing.
Some recommendations: consider testing at >200 copies/mL in virologic failure or specific contexts; testing may be unsuccessful at low-level viremia but still considered.

Note

Conflict with Government Policy

If there is any conflict between this policy and applicable government policy (e.g., LCDs/NCDs for Medicare or state Medicaid rules), the government policy supersedes this policy for the affected member.

Follow applicable LCD/NCD/Medicaid or state rules when they conflict with this policy.
Verify requirements for Medicare/Medicaid members prior to ordering.

Documentation Required

Required Clinical Documentation

Providers must include clinical documentation to support medical necessity. Documentation should demonstrate the indication, patient age, timing (entry into care, pregnancy, virologic failure), prior ART history, and clinical rationale for testing.

Indicate the clinical reason: entry into care, treatment initiation, virologic failure, pregnancy, suboptimal response, noncompliance, or planned regimen modification.
Include patient age, prior resistance test results if available, ART history, current viral load and dates, and pregnancy status when applicable.

Documentation Required

Review Prior Resistance Tests

All prior and current drug-resistance test results should be reviewed and considered when constructing or modifying ARV regimens.

Attach and review prior resistance reports with new test requests.
Document how prior results influence current regimen decisions.

Documentation Required

Documentation of Screening and Pregnancy Testing

Follow recommended screening and pregnancy-testing documentation per pediatric and obstetric guidance. For youth and pregnant persons, document screening timing and results in the medical record per AAP/Bright Futures and USPSTF/CDC recommendations.

For adolescents: document HIV screening per AAP/Bright Futures (annual for increased risk; at least once between 15–18).
For pregnant persons: document HIV screening results and timing; screen all pregnant women including those in labor with unknown status.

Note

No Additional Documentation Specified

No specific additional documentation requirements are specified in some reference segments; however, providers should retain all clinical notes, lab reports, and justification used to support testing requests.

If payer requests, be prepared to supply clinical notes, prior test reports, ART history, viral load data, and pregnancy test results.

Note

ART Initiation and Resistance Testing Timing

Initiation of ART should not be delayed while awaiting resistance testing results in pregnant persons or when rapid treatment is indicated; begin ART and modify the regimen later if resistance results necessitate changes.

Start ART promptly when indicated (including in pregnancy) and adjust regimen if resistance testing later indicates need.
Order genotypic testing at entry into care; ensure integrase testing is included if INSTI resistance is a concern.

Note

Proviral DNA Genotyping Use

Proviral DNA genotyping may be useful when plasma RNA genotyping is unlikely to succeed — for example, patients with undetectable viral load, low-level viremia, multiple prior virologic failures, or when prior resistance history is unavailable — but routine proviral DNA genotyping is not recommended.

Consider proviral DNA genotyping in persons with HIV RNA below detection or low-level viremia planning regimen changes.
Be cautious: proviral DNA may miss prior mutations or detect clinically irrelevant mutations; document rationale for use.

Step Therapy

There are no step therapy requirements specified in the cited guidance for resistance testing or HIV screening in these reference segments.

No step-therapy sequences required for ordering resistance testing per referenced guidance.
Verify member-specific benefit design for any payer-imposed step requirements.

Billing Rule

Procedure Codes (Provider Billing Note)

Procedure codes that may be used for ordering, billing, or prior authorization requests are listed below. Use these codes as a reference and verify payer-specific billing rules.

CPT/HCPCS examples include: 86689, 86701, 86702, 86703, 87389, 87390, 87391, 87534, 87535, 87536, 87537, 87538, 87539, 87806, 87900, 87901, 87903, 87904, 87906, 0219U, G0432, G0433, G0435, G0475, S3645.
Note: 0219U = targeted viral NGS (PR/RT/INT) algorithm reported as prediction of antiviral drug susceptibility; proprietary tests (e.g., Sentosa SQ) may appear with vendor-specific codes.

ART/ARV definitionART (antiretroviral treatment/therapy) and ARV (antiretroviral) refer to medications used to treat HIV infection

PurposeUsed to suppress viral replication, achieve viral suppression, and reduce progression to AIDS

Context in policyResistance testing guides selection and modification of ART regimens

Virological change thresholds (magnitude and reference)

Virological change considered meaningfulA change ≥0.5 log10 (≈threefold) in HIV‑1 RNA is required to be biologically relevant

200 copies/mL referenceA 200 copies/mL threshold improves inter-assay agreement and is referenced in defining virological failure

Transient risesTransient viral RNA increases can occur with intercurrent illness or vaccination and usually return to baseline within one month

Viral load — plasma HIV RNA level used to assess response and guide testing

Viral load definitionPlasma HIV RNA level measured by quantitative assays used to assess response to ART and guide testing and management

Role in decision-makingPre-treatment viral load informs initial regimen selection and thresholds determine likelihood of successful resistance testing

Monitoring noteUse the same assay platform for longitudinal monitoring to ensure consistent interpretation

Genotypic vs Phenotypic testing — roles and indications

Genotypic testing roleDetects resistance-associated mutations in viral genes and is preferred for initial and virologic‑failure evaluations

Phenotypic testing roleAssesses actual drug susceptibility in vitro and is indicated for suspected multidrug or complex resistance patterns

Combined usePhenotypic testing may be added to genotypic testing for complex mutation patterns (recommended supplemental role)

Genotypic resistance testing preference

Preference for genotypic testingGenotypic resistance testing is generally preferred to guide therapy in ART‑naive and many treatment‑experienced patients

Situations to include integrase testingIf transmitted INSTI resistance is suspected or prior CAB‑LA exposure, ensure genotyping includes integrase (may need separate order)

Testing timingPerform genotypic testing while on ART or within 4 weeks of stopping non‑long‑acting agents when evaluating virologic failure

Phenotypic resistance testing supplemental role

Phenotypic testing supplemental roleAdd phenotypic testing to genotypic testing for patients with known or suspected complex drug‑resistance patterns

When usedRecommended when genotypic patterns suggest multidrug resistance or when phenotypic susceptibility data are required for regimen selection

Interpretation cautionPhenotypic testing is generally supplemental and not routinely required for first‑line decision making

Definition: RT-PCR assay (examples and context)

RT‑PCR assay definitionAn in vitro reverse transcription–polymerase chain reaction assay for quantitation of HIV‑1 RNA in plasma (examples: Abbott RealTime, COBAS TaqMan, Aptima)

Performance characteristicsThese RT‑PCR assays detect ~20–40 copies/mL and have broad linear ranges up to at least 10 million copies/mL

Regulatory noteAll three primary RT‑PCR tests referenced are FDA‑approved for HIV‑1 quantitation

Definition: Geenius HIV-1/2 Supplemental Assay

Geenius assay definitionGeenius HIV‑1/2 Supplemental Assay is an FDA‑approved single‑use immunochromatographic test to confirm and differentiate HIV‑1 and HIV‑2 antibodies in serum or plasma

Use caseIntended as a supplemental confirmatory test for repeatedly reactive screening assays

Operational noteResults are interpreted with the Geenius Reader and dedicated software

Definition: Laboratory-developed test (LDT)

Laboratory‑developed test (LDT)A test developed, validated, and performed in‑house by a laboratory and regulated under CLIA as a high‑complexity test; not FDA‑cleared/approved

Coverage implicationPayer may require documentation of laboratory validation for coverage of LDTs

Regulatory contextLDTs are not FDA‑approved but are permitted for clinical use under CLIA, per current practice

Next-Generation Sequencing (NGS) for HIV resistance — referenced evaluations

NGS for HIV resistance — referenced evaluationsNext‑generation sequencing platforms have published performance evaluations for HIV‑1 DNA genotypic resistance testing (e.g., Vela Dx Sentosa, PLoS One evaluations)

Comparative performanceNGS evaluations are cited in the policy references comparing NGS to other genotyping methods and discussing analytical performance

Interpretation caveatPerformance characteristics vary by platform; results should be interpreted in clinical context and laboratory validation is necessary

Viral load assays — comparative performance at low viral loads

Comparative performance at low viral loadsComparative studies show high concordance among real‑time RT‑PCR assays but increased variation at lower limits of quantitation; assay performance at low VLs is specifically evaluated in referenced literature

Assay variability considerationVariation and error tend to increase near the lower limit of quantitation; this underlies use of higher thresholds for agreement (eg, 200 copies/mL)

Systematic review supportSystematic reviews and international collaborations are cited assessing viral load technology performance at low VL levels